Biotech
4 Early-Stage Startups Building Tools for Biopharma R&D
DealBio tracks early-stage life science tool startups across Europe and North America. These 4 are building B2B products for measurement, quality control and human-relevant research in biopharma R&D.
- B2B
- Protein Analysis
- Lab Instruments
- Cell Therapy
- Tissue Engineering
Biopharma R&D is a sequence of high-cost decisions: which protein construct to advance, which production cell line to scale, whether a cell-therapy product is behaving as intended, and how a candidate performs in a human-relevant model before clinical testing. Tools that make those decisions earlier or with better resolution can reduce wasted experiments, shorten iteration cycles and improve the quality of evidence carried into later development.
The four startups here are building around that leverage point. Their products sit inside existing R&D workflows rather than at the therapeutic endpoint, giving them a different path to validation: usefulness can show up through better measurements, faster screening, repeat adoption and integration into biopharma research long before a drug reaches the market.
At a Glance
- UNOMRSwitzerland2025Single-molecule protein modification analysis
- Constellate ProteomicsNetherlands2025Earlier antibody quality screening
- BlueRay PrecisionGermany2025CAR-T detection reagents
- AsemblisSwitzerland20253D human fat-tissue models
01
UNOMR
Building nanopore sensors that analyze protein modifications one molecule at a time.
- Country
Switzerland- Founded
- 2025
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why UNOMR stands out
UNOMR combines published ETH Zurich nanopore research with an early industrial application. A current Nestlé project is testing single-protein glycosylation measurement, placing the platform directly inside an R&D question around protein characterization rather than positioning it as a general analytical instrument.
What UNOMR is building
The platform uses a tunable interface nanopore to measure proteins and post-translational modifications at single-molecule resolution. Its first application focuses on glycosylation, with serial re-reads designed to improve confidence on individual molecules.
Building single-molecule tools to screen antibody quality earlier in development.
- Country
Netherlands- Founded
- 2025
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why Constellate Proteomics stands out
Constellate Proteomics has €535,000 in financing and public support behind its spinout and says its TU Delft setup is operational for biopharma and CDMO pilots. The R&D value is earlier antibody-quality information, which can help teams compare cell lines before committing more time to growth and purification.
What Constellate Proteomics is building
RAYmAb captures antibodies directly from crude culture supernatant and is designed to measure titre, glycosylation, aggregation and charge variants from one sample. The goal is to help teams rank production cell lines before conventional quality testing would normally be available.
Developing research reagents to detect and measure CAR-T cells.
- Country
Germany- Founded
- 2025
- Sector
- Biotech
- Funding stage
- Seed or earlier
Why BlueRay Precision stands out
BlueRay Precision reagents are used in research workflows at DKFZ, Heidelberg University Hospital and University Hospital Erlangen. Their role in biopharma R&D is measurement: giving cell-therapy teams a standardized way to compare CAR-T populations with conventional flow-cytometry equipment.
What BlueRay Precision is building
The startup develops CD19 and BCMA antigen-based reagents for measuring CAR-T cells by flow cytometry. Engineered proteins and controlled labelling are designed to reduce nonspecific staining and batch-to-batch variation.
04
Asemblis
Building 3D human fat-tissue models for obesity drug development.
- Country
- Switzerland
- Founded
- 2025
- Sector
- Biotech
- Funding stage
- Seed or earlier
- Founders
Why Asemblis stands out
Asemblis has a commercial partnership with Viscofan BioEngineering covering Fibercoll-Flex collagen bioink and joint 3D tissue-model work. Its fit with biopharma R&D is the use of human fat-tissue models to test obesity and metabolic-drug questions before clinical development.
What Asemblis is building
Asemblis develops biofabricated human fat-tissue models for obesity and metabolic drug research. The models are intended to study inflammation, weight regain, muscle loss and safety signals in a more human-relevant preclinical system, with projects scoped around partner research questions.
Deal Sourcing for Investors
Looking for More Startups Like These?
DealBio helps investment teams discover, research, and monitor early-stage healthcare and life sciences startups aligned with their investment criteria.
Investment perspective
The commercial test for a research tool is simple: does it help a team make a better decision soon enough to matter? These four products bring useful information earlier into protein, cell-therapy or preclinical work.
For investors, that creates a different path from therapeutics. Research-tool startups can demonstrate value through adoption, repeat use and integration into R&D workflows before a clinical programme exists. The science creates the moat, but the buyer decides whether that science is useful enough to become routine.
Methodology
DealBio selected these startups from its database of early-stage health and longevity startups, focusing on B2B research tools used in biopharma or translational R&D. The selection spans protein analysis, antibody development, cell-therapy measurement and human tissue models.
DealBio builds its Startup Briefs using publicly available company materials, ecosystem sources, market references and professional profiles.